Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Loratadine

FDA-approved product (tablet, oral), marketed as Alavert, Children's Claritin, Claritin and 5 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Loratadine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic disease
  • Allergic rhinitis
  • Pruritus
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Urticaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antihistamines for systemic use
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Loratadine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Loratadine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain

    NCT01311336 · start 2011-05

    Registered record
    Registry ID
    NCT01311336
    Conditions
    Pegfilgrastim-induced Back and Leg Pain
    Interventions
    Loratadine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-05
    Completion
    2013-06
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPegfilgrastim-induced Back and Leg Pain
    InterventionLoratadine; placebo
    PhasePhase 2
    Registry statusUnknown

  • Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

    NCT01154153 · start 2010-06

    Registered record
    Registry ID
    NCT01154153
    Conditions
    Rhinitis, Allergic, Perennial and/or Seasonal
    Interventions
    Placebo nasal spray; Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ); Placebo nasal spray; Claritin® Syrup
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-06
    Completion
    2010-10
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial and/or Seasonal
    InterventionPlacebo nasal spray; Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ); Placebo nasal spray; Claritin® Syrup
    PhasePhase 4
    Registry statusCompleted

  • Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists

    NCT01007864 · start 2010-01

    Registered record
    Registry ID
    NCT01007864
    Conditions
    Idiopathic Parkinson's Disease
    Interventions
    piribedil; pramipexole or ropinirole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-01
    Completion
    2011-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Parkinson's Disease
    Interventionpiribedil; pramipexole or ropinirole
    PhasePhase 3
    Registry statusCompleted

  • Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis

    NCT01055756 · start 2010-01

    Registered record
    Registry ID
    NCT01055756
    Conditions
    Allergic Rhinitis
    Interventions
    Loratadine + Pseudoephedrine sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2010-01
    Completion
    2010-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionLoratadine + Pseudoephedrine sulfate
    PhasePhase 3
    Registry statusWithdrawn

  • A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis

    NCT00796211 · start 2008-11

    Registered record
    Registry ID
    NCT00796211
    Conditions
    Plaque Psoriasis
    Interventions
    CRx-197; CRx-197; Nortriptyline; Calcipotriol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11
    Completion
    2009-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionCRx-197; CRx-197; Nortriptyline; Calcipotriol +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers

    NCT00721331 · start 2008-07

    Registered record
    Registry ID
    NCT00721331
    Conditions
    Atopic Dermatitis
    Interventions
    nortriptyline HCl + loratadine; nortriptyline HCl + loratadine; nortriptyline HCl; mometasone furoate; Active ingredient free vehicle cream of CRx-197
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-07
    Completion
    2008-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    Interventionnortriptyline HCl + loratadine; nortriptyline HCl + loratadine; nortriptyline HCl; mometasone furoate +1 more
    PhasePhase 1
    Registry statusCompleted

  • Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)

    NCT00730912 · start 2008-06

    Registered record
    Registry ID
    NCT00730912
    Conditions
    Perennial Allergic Rhinitis
    Interventions
    loratadine; loratadine; loratadine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-06
    Completion
    2008-12
    Enrolment
    261

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerennial Allergic Rhinitis
    Interventionloratadine; loratadine; loratadine
    PhasePhase 4
    Registry statusCompleted

  • Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)

    NCT00762983 · start 2008-03

    Registered record
    Registry ID
    NCT00762983
    Conditions
    Rhinitis, Allergic, Seasonal; Rhinitis, Allergic, Perennial; Urticaria; Pruritus
    Interventions
    loratadine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-03
    Completion
    2009-02
    Enrolment
    1,003

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Seasonal; Rhinitis, Allergic, Perennial; Urticaria; Pruritus
    Interventionloratadine
    PhaseNot recorded
    Registry statusCompleted

  • Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

    NCT00449072 · start 2007-03

    Registered record
    Registry ID
    NCT00449072
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    Placebo; Placebo; TAA-AQ, Nasacort® AQ; Claritin®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-03
    Completion
    2011-10
    Enrolment
    299

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionPlacebo; Placebo; TAA-AQ, Nasacort® AQ; Claritin®
    PhasePhase 4
    Registry statusCompleted

  • Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)

    NCT00423995 · start 2006-11-01

    Registered record
    Registry ID
    NCT00423995
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Loratadine/montelukast combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-11-01
    Completion
    2007-03-10
    Enrolment
    379

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionLoratadine/montelukast combination
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study of Loratadine Orally Disintegrating Tablets 10 mg Under Fed Conditions

    NCT00776282 · start 2006-07

    Registered record
    Registry ID
    NCT00776282
    Conditions
    Healthy
    Interventions
    loratadine 10 mg orally disintegrating
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-07
    Completion
    2006-09
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionloratadine 10 mg orally disintegrating
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions

    NCT00776217 · start 2006-06

    Registered record
    Registry ID
    NCT00776217
    Conditions
    Healthy
    Interventions
    loratadine 10 mg orally disintegrating tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-06
    Completion
    2006-09
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionloratadine 10 mg orally disintegrating tablets
    PhaseNot applicable
    Registry statusCompleted

  • Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)

    NCT00319995 · start 2006-03-01

    Registered record
    Registry ID
    NCT00319995
    Conditions
    Rhinitis, Allergic, Seasonal
    Interventions
    loratadine; montelukast
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-03-01
    Completion
    2006-06-28
    Enrolment
    1,095

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Seasonal
    Interventionloratadine; montelukast
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis

    NCT00524836 · start 2003-09

    Registered record
    Registry ID
    NCT00524836
    Conditions
    Rhinitis; Allergic; Perennial
    Interventions
    levocetirizine dihydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-09
    Completion
    2004-02
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis; Allergic; Perennial
    Interventionlevocetirizine dihydrochloride
    PhasePhase 3
    Registry statusCompleted

  • To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis

    NCT00525278 · start 2003-08

    Registered record
    Registry ID
    NCT00525278
    Conditions
    Rhinitis; Allergic; Seasonal
    Interventions
    Levocetirizine dihydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-08
    Completion
    2003-10
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis; Allergic; Seasonal
    InterventionLevocetirizine dihydrochloride
    PhasePhase 3
    Registry statusCompleted